Leadership

With a vision of conquering GI disease, Vivelix is committed to delivering innovative products and services that improve the lives of patients suffering from gastrointestinal and liver diseases.

Formed in March 2016, Vivelix is founded and staffed by an experienced team of gastroenterology drug developers and marketers, and funded by private equity investment.

The leadership team consists of eight former employees of Salix Pharmaceuticals, Inc. with more than 165 years of collective clinical, drug development, business development and commercialization experience, including over 75 years of experience in gastroenterology and hepatology. This same management team held direct responsibility for successfully licensing, developing, and commercializing numerous leading and transformative products for the gastroenterology and hepatology community, their patients and caregivers.

Leadership Team

William P. Forbes, Pharm.D., Founder & President and Chief Executive Officer

As the Founder & President, CEO of Vivelix Pharmaceuticals, Bill brings over 25 years of acknowledged, executive leadership experience and skills to Vivelix Pharmaceuticals.

Prior to founding Vivelix, Bill served as President, Medical, Research & Development and Chief Development Officer of Salix Pharmaceuticals until its sale to Valeant Pharmaceuticals in 2015.

As a corporate officer and head of Medical and R&D his responsibilities included areas of corporate communication, governance, compliance, planning, operations, strategy and management. During his tenure at Salix, Bill successfully guided 12 FDA approvals which contributed to the tremendous increase in value of the company over this time with a market capitalization of ~$500 M in 2005 to ~$11 B when it was acquired in April 2015.

Prior to Salix, Bill served as Vice President of Clinical Development and Regulatory Affairs of Metabasis (2002-2004) and in increasing positions of responsibility at Otsuka (1991-2002) and Glaxo (1989-1991).

During his diverse career, Bill has contributed to the approval of numerous marketing applications by health authorities including sNDAs and NDAs for: XIFAXAN550® (HE in CLD 2010, IBS 2015), RELISTOR® (Subcutaneous, OIC 2014; Oral, OIC 2016), RUCONEST® (HAE 2015), UCERIS® RECTAL FOAM (Distal UC 2015), FULYZAQ® (HIV-associated Diarrhea, 2012), GIAZO® (Acute UC, 2012), METOZOLV ODT® (Gastroparesis, 2009), APRISO® (Maintenance of Remission in UC, 2008), OSMOPREP® and MOVIPREP® (Bowel cleansing for colonoscopy, both 2006), COLAZAL® (Pediatric use in Acute UC, 2005), PLETAL® (Intermittent Claudication in PAD, 1999).

Bill received his Doctor of Pharmacy at Creighton University in 1987, where he was also a Cardiovascular Research Fellow and Clinical Research Fellow (1987-1989). As an experienced researcher, Bill has authored or co-authored over 48 published manuscripts.

Enoch B. Bortey, Ph.D., Founder & Chief Development Officer

In his role as Chief Development Officer, Enoch brings more than 24 years pharmaceutical experience to Vivelix, including experience in global project management, statistical and clinical operations support for phases I-IV clinical trials in the areas of vaccines, gastroenterology, central nervous system, respiratory, drug delivery systems, anti-infectives, cardiovascular, and bone disease.

Before joining Vivelix, Enoch served as the Vice President, Clinical Biostatistics and Data Systems for BioDelivery Systems International where he was responsible for global design and development of the biostatistics function, translating the development strategies into tactical plans to support product development objectives.

Prior to his tenure at BioDelivery Systems, Enoch was the Senior Vice President, Clinical Operations and Biometrics for Salix Pharmaceuticals, Inc. where he contributed to the approval of numerous marketing applications by health authorities including sNDAs and NDAs for: XIFAXAN550® (HE in CLD 2010, IBS 2015), RELISTOR® (OIC 2014), RUCONEST® (HAE 2015), UCERIS® RECTAL FOAM (Distal UC 2015), FULYZAQ® (HIV-associated Diarrhea, 2012), GIAZO® (Acute UC, 2012), METOZOLV ODT® (Gastroparesis, 2009), and APRISO® (Maintenance of Remission in UC, 2008).

Enoch has authored and co-authored 24 published articles and has led statistical efforts for regulatory filings (including European submissions), participated in FDA Advisory Committee Meetings and several other meetings with the FDA and European regulatory authorities.

Enoch earned a B.Sc. in Mathematics from the University of Science and Technology, Kumasi, Ghana; a M.Sc. Statistics from Queen's University, Kingston, Ontario, Canada, and a Ph.D. in Biostatistics from the Medical College of Virginia, Virginia Commonwealth University.

Craig A. Paterson, M.D., M.Sc., M.B.A., Founder & Chief Medical Officer

Craig A. Paterson is Founder & Chief Medical Officer of Vivelix Pharmaceuticals. An experienced pharmaceutical executive, Craig brings over 25 years of combined clinical practice, research and drug development experience.  His background includes leadership roles as an academic surgeon at McMaster University and an Associate Professor and Chief of Colon and Rectal Surgery at the University of Massachusetts, as well as a pharmaceutical resume’ that includes clinical research, drug development, lifecycle planning, and strategic portfolio management.

Prior to his role at Vivelix, Craig has held positions of increasing responsibility including Chief Medical Officer where he has provided leadership as well as medical and scientific oversight for R&D functions including clinical development, clinical operations, biometrics, drug safety, medical writing and medical affairs.

At Salix Pharmaceuticals he held leadership roles in Medical and Clinical Development, including the role of Senior Vice President, Medical & Clinical Development prior to the company’s acquisition.  Craig contributed to the approval of numerous marketing applications by health authorities while at Salix including sNDAs and NDAs for: XIFAXAN550® (IBS 2015), RELISTOR® (Subcutaneous, OIC 2014; Oral, OIC 2016), RUCONEST® (HAE 2015), UCERIS® RECTAL FOAM (Distal UC 2015), FULYZAQ® (HIV-associated Diarrhea, 2012) and GIAZO® (Acute UC, 2012). He also led all R&D and medical integration activities associated with the acquisition of Santarus, Inc.

Craig obtained his undergraduate degree in chemistry, Doctor of Medicine and a Master of Science degree in physiology and pharmacology all at McMaster University and in 2006 earned his M.B.A. at the University of Tennessee.  He completed a General Surgery Residency at McMaster University as well as a fellowship in Colon and Rectal Surgery at the Mayo Clinic.

Daniel P. Lundberg, Founder & Chief Marketing Officer

Dan brings over 25 years of results-oriented, sales, marketing, project management, business development and commercial operations leadership to his role as Chief Marketing Officer, Vivelix Pharmaceuticals. Prior to joining Vivelix, Dan was Founder & President of Pharmtegrity Consulting Services LLC, focusing on the pharmaceutical, biotechnology and device industries. For over thirteen years, Dan held roles of increasing responsibility within the marketing group at Salix Pharmaceuticals, Inc., culminating in his role as Senior Vice President, Marketing, where he led in-line and new product marketing, marketing research and digital marketing, and played an important role as part of the Senior Executive Team responsible for shaping corporate strategy. While at Salix, Dan held P&L responsibility and oversight for a GI product portfolio, including such brands as XIFAXAN®, APRISO®, UCERIS® and RELISTOR®, with demand net revenue of over $1.4 billion dollars.

Prior to Salix, Dan served in various sales, domestic and global marketing, project management and business development capacities for GelTex Pharmaceuticals Inc., Wyeth-Ayerst International, and Organon Inc. Dan has worked in over 25 disease/therapeutic areas, and contributed to numerous product launch teams, co-promotion, licensing and/or merger & acquisition agreements during his wide-ranging career.

Dan earned a B.S., Biology from Virginia Polytechnic Institute and State University (Virginia Tech) in 1988.

Pamela L. Golden, Ph.D., Founder & Vice President, Nonclinical and Clinical Pharmacology

As Founder & Vice President, Nonclinical and Clinical Pharmacology, Pam brings over 17 years of nonclinical and clinical pharmacology expertise in the pharmaceutical industry. Pam earned her B.S. in Pharmacy and Ph.D. in Pharmaceutics from The University of North Carolina at Chapel Hill, followed by postdoctoral training at the UCLA School of Medicine and an assistant professorship at the Medical University of South Carolina.

During her career, Pam has contributed to eight IND submissions and seven NDA/sNDA approvals, served as an editorial advisory board member and reviewer for multiple scientific publications, and has authored or co-authored 23 peer-reviewed publications.

Prior to Vivelix, Pam served as Associate Vice President, Nonclinical and Clinical Pharmacology at Salix Pharmaceuticals where she contributed to the regulatory approvals of multiple GI and hepatology products, including XIFAXAN550® (HE in CLD 2010, IBS 2015), FULYZAQ® (HIV-associated Diarrhea, 2012), UCERIS® RECTAL FOAM (Distal UC 2015), and RELISTOR® (Subcutaneous, OIC 2014; Oral, OIC 2016). Prior to Salix, Pam held positions of increasing responsibility at DuPont Pharmaceuticals and GlaxoSmithKline, working in therapeutic areas including neurology and anti-infectives.

Christopher A. Martin, M.S., Founder & Executive Director, CMC Operations

Christopher Martin is Founder & Executive Director, CMC Operations of Vivelix Pharmaceuticals. Chris is known in the industry as a results-driven Pharmaceutical R&D expert with nearly 20 years of industry experience in key technical, management and leadership positions with emphasis in pharmaceutical formulation and process development, analytical development, clinical and commercial-scale manufacturing, CMC regulatory operations, and quality assurance management.

Prior to Vivelix, Chris contributed to the success of Salix for 10 years through his roles in directing CMC regulatory activities for all Salix products, including sNDAs and NDAs for: XIFAXAN550® (HE in CLD 2010, IBS 2015), RELISTOR® (Subcutaneous, OIC 2014; Oral, OIC 2016), UCERIS® RECTAL FOAM (Distal UC 2015), FULYZAQ® (HIV-associated Diarrhea, 2012), GIAZO® (Acute UC, 2012), METOZOLV ODT® (Gastroparesis, 2009), APRISO® (Maintenance of Remission in UC, 2008), OSMOPREP® and MOVIPREP® (Bowel cleansing for colonoscopy, both 2006) and COLAZAL® (Pediatric use in Acute UC, 2005), amongst others.

Chris also held laboratory and analytical management positions at Varian, Inc. and AAI International.

Chris acquired his undergraduate degree in biology at the University of North Carolina, Chapel Hill, and his Master’s Degree in Marine Biology at the University of North Carolina, Wilmington where he also served as a graduate assistant.

Corey M. Hansen, M.B.A., Executive Director, Strategic Planning & Business Development

As Executive Director of Strategic Planning & Business Development, Corey brings greater than 20 years of increasing responsibilities in business development, competitive intelligence, marketing research, business analytics and strategic planning. Prior to Vivelix, Corey was Sr. Director, Global Business Intelligence at United Therapeutics. In that role, Corey provided key input into the go/no go decisions for potential acquisition candidates. Prior to United Therapeutics, Corey served as Sr. Director, Marketing Research and Strategic Analysis at Salix Pharmaceuticals where he managed commercial analytics support to sales & marketing, business development, finance, accounting, legal, medical, R&D, regulatory and managed markets. While at Salix, Corey was involved in assessing a variety of corporate development opportunities, including acquisitions of Oceana Therapeutics and Santarus, inversion deal with Cosmo Pharmaceuticals, and eventual company sale to Valeant Pharmaceuticals.

Corey’s previous experience includes tenures at Dey Pharma (Mylan Specialty Division), Frost & Sullivan Growth Consulting, Hatteras Venture Partners and Miravant Pharmaceuticals.

Corey has a B.S. in Pharmacology from the University of California, Santa Barbara, and earned an M.B.A. from the University of North Carolina, Chapel Hill, Kenan-Flagler Business School.

Jill Aremia, Founder & Director, Outsourcing, Financial & Project Management

Jill brings to Vivelix 23 years of experience in pharmaceutical outsourcing, contracting, and budgetary planning & analysis. She is known for her ability to work effectively with internal and external customers, building relationships both inside and outside of client groups. Jill is a skilled negotiator recognized for her analytical, organizational, and creative skills, and has managed R&D budgets of over $150M.

Prior to Vivelix, Jill served as Director, Development Outsourcing at Array Biopharma, Inc, and previously served for over seven years at Salix Pharmaceuticals culminating in the role of Associate Director, Contracts & Finance, Medical and R&D.

Jill earned a B.S. Business Administration degree at NC Wesleyan College, Raleigh, North Carolina.